Jean-Francois Jasmin

Associate Provost for Research and Graduate Education

Associate Professor, Department of Pharmaceutical Sciences

University of the Sciences

600 S. 43rd Street

McNeil Building, room 104

Philadelphia, PA 19104

Tel: 215-596-8512

j.jasmin@usciences.edu

Education

EDUCATION

1995-1998 B.S. University of Montreal, Montreal, Canada (Biology)

1998-2004 Ph.D University of Montreal, Montreal, Canada (Physiology)

POSTGRADUATE TRAINING

2003-2004 Visiting Scientist Albert Einstein College of Medicine, Bronx, NY

(Department of Molecular Pharmacology)

2004-2006 Post-Doctoral Fellow Albert Einstein College of Medicine, Bronx, NY

(Department of Molecular Pharmacology)

2006-2007 Post-Doctoral Fellow Thomas Jefferson University, Philadelphia, PA

(Department of Cancer Biology)

Employment History

2007-2010 Instructor (tenure-track), Departments of Cancer Biology and Stem Cell Biology & Regenerative Medicine, Thomas Jefferson University, Philadelphia, PA

2010-2013 Assistant Professor (tenure-track), Department of Stem Cell Biology & Regenerative Medicine, Thomas Jefferson University, Philadelphia, PA

2013-2015 Research Assistant Professor, Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA

2014-present Associate Provost for Research and Graduate Education, University of the Sciences, Philadelphia, PA

2015-present Associate Professor with Tenure, Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA

Honors and Awards

2000 - Excellence Award from the College of Graduate Studies at the University of Montreal (Montreal, Canada)

2001 - Predoctoral Fellowship from the Canadian Institutes of Health Research (CIHR) and the Heart and Stroke Foundation of Canada (HSFC) Partnership (2001-2003)

- Predoctoral Fellowship from the "Fonds de la Recherche en Santé du Québec" (FRSQ, Quebec Health Research Foundation) (2001-2003)

- Excellence Award from the College of Graduate Studies at the University of Montreal (Montreal, Canada)

2002 - Excellence Award from the College of Graduate Studies at the University of Montreal (Montreal, Canada)

2003 - Postdoctoral Research Fellowship from the "Fonds de la Recherche en Santé du Québec" (FRSQ, Quebec Health Research Foundation) (2003-2004)

2004 - Postdoctoral Research Fellowship from the Heart and Stroke Foundation of Canada (HSFC) (2004-2006)

2006 - Postdoctoral Research Fellowship from the Canadian Institutes of Health Research (CIHR) (2006-2008)

2015 - Dean’s Award for Research & Scholarly Activity, Philadelphia College of Pharmacy, University of the Sciences (Philadelphia, PA)

Publications

Citations: 1767 (google scholar)

h-index: 24 (google scholar)

*** indicates where Dr. Jasmin is the corresponding author

Original Articles:

1- Dupuis J, Jasmin JF, Prié S, Cernacek P. Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther. 2000;13(3):135-40.

2- Lucas M, Jasmin JF, Dupuis J. Effect of ET(A) receptor antagonist on pulmonary hypertension and vascular reactivity in rats with congestive heart failure. Pulm Pharmacol Ther. 2001;14(4):307-14.

3- Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001 Jan 16;103(2):314-8.

4- Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, Pourdjabbar A, Jasmin JF, Sarrazin JF, Liu P, Adam A, Butany J, Rouleau JL. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation. 2002 May 28;105(21):2549-55.

5- Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res. 2003 Jun 1;58(3):621-31.

6- Jasmin JF, Cernacek P, Dupuis J. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. Clin Sci (Lond). 2003 Dec;105(6):647-53.

7- Jasmin JF, Dupuis J. Evaluation of luminal endothelin-converting enzyme activity in the pulmonary and coronary circulations. J Cardiovasc Pharmacol. 2004 Jan;43(1):21-5.

8- Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry. 2004 Jul 6;43(26):8312-21.

9- Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis J, Lisanti MP. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res. 2004 Sep 1;63(4):747-55.

10- Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, Jasmin JF, Czaja MT, Lin EY, Armstrong RC, Pollard JW, Kitsis RN. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ. 2005 Jun;12(6):682-6.

11- Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation. 2006 Aug 29;114(9):912-20.

12- Lefebvre F, Préfontaine A, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J. Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond). 2006 Sep;111(3):217-24.

13- Jasmin JF, Malhotra S, Singh Dhallu M, Mercier I, Rosenbaum DM, Lisanti MP. Caveolin-1 deficiency increases cerebral ischemic injury. Circ Res. 2007 Mar 16;100(5):721-9.

14- Gioiosa L, Raggi C, Ricceri L, Jasmin JF, Frank PG, Capozza F, Lisanti MP, Alleva E, Sargiacomo M, Laviola G. Altered emotionality, spatial memory and cholinergic function in caveolin-1 knock-out mice. Behav Brain Res. 2008 Apr 9;188(2):255-62.

15- Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN. ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle. 2008 Jun 1;7(11):1640-7.

16- Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther. 2008 Aug;7(8):1212-25.

17- Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, Jiménez SA. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008 Sep;58(9):2854-65.

18- Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol. 2009 Apr;174(4):1172-90.

19- Mercier I, Bryant KG, Sotgia F, Bonuccelli G, Witkiewicz AK, Dasgupta A, Jasmin JF, Pestell RG, Lisanti MP. Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1(P132L) mutation. Cell Cycle. 2009 May 1;8(9):1396-401.

20- Jasmin JF***, Yang M, Iacovitti L, Lisanti MP. Genetic ablation of caveolin-1 increases neural stem cell proliferation in the subventricular zone (SVZ) of the adult mouse brain. Cell Cycle. 2009 Dec;8(23):3978-83.

21- Park HC, Yasuda K, Ratliff B, Stoessel A, Sharkovska Y, Yamamoto I, Jasmin JF, Bachmann S, Lisanti MP, Chander P, Goligorsky MS. Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. Am J Physiol Renal Physiol. 2010 Feb;298(2):F357-64.

22- Ratliff BB, Singh N, Yasuda K, Park HC, Addabbo F, Ghaly T, Rajdev M, Jasmin JF, Plotkin M, Lisanti MP, Goligorsky MS. Mesenchymal stem cells, used as bait, disclose tissue binding sites: a tool in the search for the niche? Am J Pathol. 2010 Aug;177(2):873-83.

23- Feiner EC, Chung P, Jasmin JF, Zhang J, Whitaker-Menezes D, Myers V, Song J, Feldman EW, Funakoshi H, Degeorge BR Jr, Yelamarty RV, Koch WJ, Lisanti MP, McTiernan CF, Cheung JY, Bristow MR, Chan TO, Feldman AM. Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3. J Card Fail. 2011 Mar;17(3):253-63.

24- Thomas NM, Jasmin JF, Lisanti MP, Iacobas DA. Sex differences in expression and subcellular localization of heart rhythm determinant proteins. Biochem Biophys Res Commun. 2011 Mar 4;406(1):117-22.

25- Jasmin JF***, Rengo G, Lymperopoulos A, Gupta R, Eaton GJ, Quann K, Gonzales DM, Mercier I, Koch WJ, Lisanti MP. Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1274-81.

26- Sharma A, Trane A, Yu C, Jasmin JF, Bernatchez P. Amlodipine increases endothelial nitric oxide release by modulating binding of native eNOS protein complex to caveolin-1. Eur J Pharmacol. 2011 Jun 1;659(2-3):206-12.

27- de Almeida CJ, Witkiewicz AK, Jasmin JF, Tanowitz HB, Sotgia F, Frank PG, Lisanti MP. Caveolin-2-deficient mice show increased sensitivity to endotoxemia. Cell Cycle. 2011 Jul 1;10(13):2151-61.

28- Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC, Fortina P, Balasubramaniam S, Knudsen KE, Schwarting R, Lisanti MP, Mercier I. Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol. 2011 Sep;43(9):1318-29.

29- Chi Y, Min J, Jasmin JF, Lisanti MP, Chang YT, Schuster VL. Development of a high-affinity inhibitor of the prostaglandin transporter. J Pharmacol Exp Ther. 2011 Nov;339(2):633-41.

30- Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, Kass DA. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res. 2012 Jan 20;110(2):295-303.

31- Wang Y, Wang X, Jasmin JF, Lau WB, Li R, Yuan Y, Yi W, Chuprun K, Lisanti MP, Koch WJ, Gao E, Ma XL. Essential role of caveolin-3 in adiponectin signalsome formation and adiponectin cardioprotection. Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):934-42.

32- Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV, Lisanti MP. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol. 2012 Jul;181(1):278-93.

33- El-Helou V, Chabot A, Gosselin H, Villeneuve L, Clavet-Lanthier ME, Tanguay JF, Enikolopov G, Fernandes KJ, Jasmin JF, Calderone A. Cardiac resident nestin(+) cells participate in reparative vascularisation. J Cell Physiol. 2013 Sep;228(9):1844-53.

34- Quann K, Gonzales DM, Mercier I, Wang C, Sotgia F, Pestell RG, Lisanti MP, Jasmin JF***. Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. Cell Cycle. 2013 May 15;12(10):1510-20.

35- Addabbo F, Chen Q, Patel DP, Rabadi M, Ratliff B, Zhang F, Jasmin JF, Wolin M, Lisanti M, Gross SS, Goligorsky MS. Glutamine supplementation alleviates vasculopathy and corrects metabolic profile in an in vivo model of endothelial cell dysfunction. PLoS One. 2013 Jun 11;8(6):e65458.

36- de Almeida CJ, Jasmin JF, Del Galdo F, Lisanti MP. Genetic ablation of caveolin-2 sensitizes mice to bleomycin-induced injury. Cell Cycle. 2013 Jul 15;12(14):2248-54.

37- Liu Y, Zhang J, Yi B, Chen M, Qi J, Yin Y, Lu X, Jasmin JF, Sun J. Nur77 Suppresses Pulmonary Artery Smooth Muscle Cell Proliferation Through Inhibition of the STAT3/Pim-1/NFAT Pathway. Am J Respir Cell Mol Biol. 2014 Feb;50(2):379-88.

38- Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, Hulit J, Gandara R, Wang C, Pestell RG, Lisanti MP, Jasmin JF***. CAPER, a novel regulator of human breast cancer progression. Cell Cycle. 2014 Apr 15;13(8):1256-64.

39- Pavlides S, Gutierrez-Pajares JL, Katiyar S, Jasmin JF, Mercier I, Walters R, Pavlides C, Pestell RG, Lisanti MP, Frank PG. Caveolin-1 regulates the anti-atherogenic properties of macrophages. Cell Tissue Res. 2014 Dec;358(3):821-831.

40- Chabot A, Meus MA, Naud P, Hertig V, Dupuis J, Villeneuve L, El Khoury N, Fiset C, Nattel S, Jasmin JF, Calderone A. Nestin is a Marker of Lung Remodeling Secondary to Myocardial Infarction and Type I Diabetes in the Rat. J Cell Physiol. 2015 Jan;230(1):170-9.

41- Chi Y, Jasmin JF, Seki Y, Lisanti MP, Charron MJ, Lefer DJ, Schuster VL. Inhibition of the prostaglandin transporter PGT lowers blood pressure in hypertensive rats and mice. PLOS One. 2015 Jun 29;10(6):e0131735.

42- Meus MA, Hertig V, Villeneuve L, Jasmin JF, Calderone A. Nestin Expressed by Pre-Existing Cardiomyocytes Recapitulated in Part an Embryonic Phenotype; Suppressive Role of p38 MAPK. J Cell Physiol. 2016 Jul 20. [Epub ahead of print]

Review Articles:

1- Jasmin JF, Mercier I, Sotgia F, Lisanti MP. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol Metab. 2006 May-Jun;17(4):150-8.

2- Mercier I, Jasmin JF, Pavlides S, Minetti C, Flomenberg N, Pestell RG, Frank PG, Sotgia F, Lisanti MP. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest. 2009 Jun;89(6):614-23.

3- Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, Jasmin JF, Frank PG, Pestell RG, Kleer CG, Sotgia F, Lisanti MP. Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. Cell Cycle. 2009 Jun 1;8(11):1654-8.

Book Chapters:

1- Jasmin JF, Frank PG, Lisanti MP. Caveolin proteins in cardio-pulmonary disease and lung cancers. Advance in Molecular and Cell Biology. Edited by Frank PG and Lisanti MP. Elsevier Ltd. 2005; 36: 211-233.

2- Lisanti MP, Jasmin JF. Caveolins. Encyclopedia of Respiratory Medicine. Edited by Laurent GF and Shapiro SD. Elsevier Ltd. 2006; 1: 328-332.

Books:

1- Caveolins and caveolae: Roles in signaling and disease mechanisms (Advances in Experimental Medicine and Biology). Edited by Jasmin JF, Frank PG and Lisanti MP. Springer; 1st Edition, 2012. http://www.springer.com/biomed/book/978-1-4614-1221-2.

2- Caveolins in cancer pathogenesis, prevention and therapy (Current Cancer Research). Edited by Mercier I, Jasmin JF and Lisanti MP. Springer; 1st Edition, 2012. http://www.springer.com/biomed /cancer/book/978-1-4614-1000-3.

3- Lisanti MP, Jasmin JF, Frank PG (Section Editors). Regeneration and scarring. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Edited by Mitchell RN and McManus LM. Elsevier, 2014. http://scitechconnect.elsevier.com/pathobiology-human-disease-dynamic-encyclopedia-disease-mechanisms#.VFg_V1ejLIU.

Abstracts:

1- Lucas M, Jasmin JF, Dupuis J. Effect of endothelin antagonists on vascular reactivity and pulmonary hypertension in the rat model of myocardial infarction. Sixth International Conference on Endothelin, Montreal, Canada, 1999.

2- Jasmin JF, Dupuis J. Superiority of mixed ET_A/B over specific ET_A antagonist in treatment of pulmonary hypertension and right ventricular hypertrophy in the monocrotaline rat model. J Am Coll Cardiol (JACC) February 2000; 35 (2,suppl.A): 323A.

3- Sia YT, Calderone A, Sarrazin JF, Jasmin JF, Rouleau JL. Cardioprotective effects of probucol in a rat model of myocardial infarction. The Canadian Cardiovascular Congress, Vancouver, Canada, 2000.

4- Jasmin JF, Dupuis J. Superiority of a non-selective ET_A/B over a selective ET_A antagonist in monocrotaline (MCT)-induced pulmonary hypertension and right ventricular hypertrophy in rats. The Canadian Cardiovascular Congress, Vancouver, Canada, 2000.

5- Sia YT, Jasmin JF, Sarrazin JF, Calderone A, Adam A, Rouleau JL. Beneficial effects of probucol on neurohormonal activation and cardiac cytokines expression in the post-infarction rat model. J Am Col Cardiol (JACC) February 2001;37(2, suppl.A): 374A.

6- Jasmin JF, Dupuis J. The lung does not remove or hydrolyse circulating big-ET-1 during a single transit time. Seventh International Conference on Endothelin, Edinburgh, Scotland, 2001.

7- Jasmin JF, Dupuis J. The lung does not remove or hydrolyse circulating big-ET-1 during a single transit time. Experimental Biology, New-Orleans, USA, 2002.

8- Jasmin JF, Dupuis J. The lung does not remove or hydrolyse circulating big-ET-1 during a single transit time. The Canadian Cardiovascular Congress, Edmonton, Canada, 2002.

9- Jasmin JF, Cernacek P, Dupuis J. Activation of the right ventricular endothelin system in the monocrotaline model of pulmonary hypertension: Response to ETA receptor blockade. Eight International Conference on Endothelin, Tsukuba, Japan, 2003.

10- Jasmin JF, Dupuis J. Evaluation of the luminal endothelin-converting enzyme activity in coronary circulation. Experimental Biology, San Diego, USA, 2003.

11- Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. American Heart Association Scientific Sessions, New-Orleans, USA, 2004.

12- Lefebvre F, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J. Activation of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. The Canadian Cardiovascular Congress, Montreal, Canada, 2005.

13- Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. A cell-permeable caveolin-1 peptide prevents the development of pulmonary hypertension and right ventricular hypertrophy. The Canadian Cardiovascular Congress, Vancouver, Canada, 2006.

14- Jasmin JF, Malhotra S, Dhallu MS, Mercier I, Rosenbaum DM, Lisanti MP. Caveolin-1 deficiency increases cerebral ischemic injury in mice. The Canadian Cardiovascular Congress, Vancouver, Canada, 2006.

15- Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short term administration of a cell-permeable caveolin-1 peptide prevents the development of pulmonary hypertension and right ventricular hypertrophy. American Heart Association Scientific Sessions, Chicago, USA, 2006.

16- Del Galdo F, de Almeida C, Jasmin JF, Lisanti MP, Jimenez S. Role of caveolin-1 in the pathogenesis of tissue fibrosis in Systemic Sclerosis. 27^th European Workshop for Rheumatology Research, Florence, Italy, 2007.

17- Chan T, Chung PH, Funakoshi H, Cheskis E, Song J, Herrmann DE, Jasmin JF, Lisanti MP, Cheung JY, Feldman AM. Overexpression of A1 adenosine receptor causes decreased cardiac contractility and abnormal calcium handling by selectively perturbing caveolin 3-associated T-tubule structure. American Heart Association Scientific Sessions, Orlando, Florida, USA, 2007.

18- Jasmin JF, Mercier I, Lisanti MP. Administration of a caveolin-1 mimetic peptide rescues the cardiac and pulmonary abnormalities observed in Cav-1 KO mice. American Heart Association Scientific Sessions, Orlando, Florida, USA, 2007.

19- Cheskis E, Chung PH, De George BR, Feldman EW, Funakoshi H, Jackson W, Jasmin JF, Koch WJ, Lisanti MP, Ma XL, Myers VD, Song J, Wagner J, Wang Y, Whitaker-Menezes D, Yelamarty RV, Zhang J, Cheung JY, Chan TO, Feldman AM. Over-expression of the A₁-adenosine receptor alters cardiac function by inhibiting production of caveolin-3. American Heart Association Scientific Sessions, Orlando, Florida, USA 2009.

20- Jasmin JF, Rengo G, Lymperopoulos A, Gupta R, Eaton GJ, Quann K, Gonzales DM, Mercier I, Koch WJ, Lisanti MP. Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction. American Heart Association Scientific Sessions, Chicago, Illinois, USA, 2010.

21- Wang Y, Gao E, Wang Y, Jasmin JF, Lau WB, Li R, Yuan Y, Yi W, Chuprun K, Lisanti MP, Koch WJ, Ma, XL. Essential role of caveolin-3 in adiponectin signalsome formation and adiponectin cardioprotection. American Heart Association Scientific Sessions, Orlando, Florida, USA 2011.

22- Bard A, Jasmin JF. CAPER, a novel biomarker and therapeutic target for human brain cancer. University of the Sciences 12^th Annual Research Day, Philadelphia, Pennsylvania, USA, 2014.

23- Campbell M, Russell A, Jasmin JF, Mercier I. Regulation of Triple Negative Breast Cancer Progression by the AP-1 Co-Activator, CAPER. University of the Sciences 13^th Annual Research Day, Philadelphia, Pennsylvania, USA, 2015.

24- Houtmann J, Salvo R, Lauver B, Bard A, Russell A, Camacho J, Schwarting R, Mercier I, Jasmin JF. CAPER as a Novel Biomarker of NSCLC Adenocarcinoma Progression. University of the Sciences 14^th Annual Research Day, Philadelphia, Pennsylvania, USA, 2016.

25- Campbell M, Russell A, Camacho J, Schwarting R, Jasmin JF, Mercier I. Regulation of Triple Negative Breast Cancer Progression by CAPER, a Novel Ap-1 Co-Activator. University of the Sciences 14^th Annual Research Day, Philadelphia, Pennsylvania, USA, 2016.